Brokerages Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Price Target at $50.57

Key Points

• Analysts have given Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) a consensus rating of "Buy", with eight research firms covering the stock.
• The average twelve-month price target for Arcturus is $50.57, although several firms have recently adjusted their price targets downward.
• Arcturus reported earnings of ($0.34) per share, surpassing estimates and generating revenue of $28.30 million for the quarter.

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) have received an average rating of "Buy" from the eight analysts that are presently covering the firm, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $50.5714.

Several research firms recently weighed in on ARCT. Citigroup reaffirmed a "buy" rating and issued a $49.00 price objective (up from $47.00) on shares of Arcturus Therapeutics in a research note on Tuesday, August 12th. Wells Fargo & Company reduced their price objective on Arcturus Therapeutics from $45.00 to $42.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 12th. Scotiabank reaffirmed an "outperform" rating on shares of Arcturus Therapeutics in a research note on Wednesday, July 2nd. Leerink Partners reduced their price objective on Arcturus Therapeutics from $63.00 to $54.00 and set an "outperform" rating on the stock in a research note on Friday, August 22nd. Finally, HC Wainwright initiated coverage on Arcturus Therapeutics in a research report on Thursday. They issued a "buy" rating and a $60.00 target price for the company.

Hedge Funds Weigh In On Arcturus Therapeutics

Several large investors have recently bought and sold shares of ARCT. Osaic Holdings Inc. raised its position in shares of Arcturus Therapeutics by 51.8% during the second quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 738 shares during the last quarter. BNP Paribas Financial Markets raised its position in shares of Arcturus Therapeutics by 163.4% during the second quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company's stock worth $54,000 after acquiring an additional 2,586 shares during the last quarter. Bank of America Corp DE raised its position in shares of Arcturus Therapeutics by 0.7% during the second quarter. Bank of America Corp DE now owns 292,429 shares of the biotechnology company's stock worth $3,805,000 after acquiring an additional 2,098 shares during the last quarter. Ameriprise Financial Inc. raised its position in shares of Arcturus Therapeutics by 378.5% during the second quarter. Ameriprise Financial Inc. now owns 72,252 shares of the biotechnology company's stock worth $940,000 after acquiring an additional 57,152 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Arcturus Therapeutics by 101.7% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 32,332 shares of the biotechnology company's stock worth $421,000 after acquiring an additional 16,306 shares during the last quarter. 94.54% of the stock is currently owned by institutional investors.

Arcturus Therapeutics Stock Down 4.6%

Shares of ARCT traded down $0.80 during trading hours on Monday, hitting $16.40. 249,848 shares of the company were exchanged, compared to its average volume of 470,696. The firm's fifty day moving average is $14.80 and its 200 day moving average is $13.40. The company has a market cap of $445.29 million, a price-to-earnings ratio of -7.35 and a beta of 2.39. Arcturus Therapeutics has a fifty-two week low of $8.04 and a fifty-two week high of $25.88.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($1.11) by $0.77. The business had revenue of $28.30 million for the quarter, compared to analyst estimates of $17.64 million. Arcturus Therapeutics had a negative return on equity of 24.87% and a negative net margin of 49.26%. Analysts anticipate that Arcturus Therapeutics will post -2.22 EPS for the current year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.